15 Oct - 7 min read

2022 Half-Year Trading Update

2022 Half-Year Trading Update

Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
("Mediclinic", the "Company", or the "Group")

15 October 2021

2022 Half-Year Trading Update

Mediclinic, the diversified international private healthcare services group, provides the following
trading update ahead of the publication of the Group’s results for the six months ended 30
September 2021 ("1H22"), scheduled for 11 November 2021. The information on which this
update is based represents the Group’s latest financial estimates and has not been reviewed
and reported on by Mediclinic’s external auditors. All financial figures, unless explicitly stated,
are adjusted (1). For comparative purposes, 1H22 is presented alongside the six months ended
30 September 2020 ("1H21") as well as the six months ended 30 September 2019 ("1H20"),
representing a pre-pandemic period.

Summary
 - Group revenue up 12%; ahead of pre-pandemic levels across all three divisions
 - Material recovery in Group EBITDA margin to around 15.5% (1H21: 12.1%)
 - Strong Group cash conversion at around 100% of EBITDA

Commenting today, Dr Ronnie van der Merwe, Group Chief Executive Officer, said:
"I’m pleased with how the Group continues to effectively navigate the ongoing impact of the
pandemic – and we are thankful to our medical professionals and employees without whom this
would not be possible. Their exemplary efforts and commitment, combined with our clinical
protocols, have enabled us to safely meet the ongoing demands for our healthcare services,
continue to deliver on our Group operational and strategic goals and, recover to pre-pandemic
revenue at all three divisions.

"Mediclinic Southern Africa has continued to treat a significant number of COVID-19 patients,
while addressing the demand for urgent and elective non-COVID-19 care. It is encouraging to
see that, as South Africa transitions out of the third wave, we are observing positive trends in
non-COVID-19 activity.

"The strong first-half delivered by Mediclinic Middle East, combined with a robust performance
at Hirslanden in Switzerland, positions us well heading into the second-half of the year."

Group overview
Despite the continued impact of and uncertainty presented by the pandemic, the Group
delivered a 12% increase in revenue compared with 1H21. The performance was driven by a
recovery in patient activity across all three divisions. Compared with pre-pandemic 1H20,
revenue was up in all three divisions and 4% at the Group, with Hirslanden and Mediclinic
Middle East delivering volumes in excess of pre-pandemic levels.

The Group delivered an EBITDA margin of around 15.5% (1H21: 12.1% and 1H20: 16.6%),
benefitting from margin improvements at all three divisions compared with 1H21. Effective cost
base management is an ongoing Group priority, including the current impact of COVID-19-                                                                                                 
related costs. Various initiatives have been established to support the return towards pre-
COVID-19 profitability at all divisions.

The Group’s cash conversion (2) continued to improve, at around 100% in 1H22 (1H21: 42%;
FY21: 77%), in line with the targeted 90-100%.

The Group’s ongoing financial discipline and resilience were demonstrated by the increase in
cash and available facilities during the first half of the year, to around £770m (1H21: £661m
and FY21: £679m). Net debt at around £2 200m (1H21: £2 391m and FY21: £2 159m) includes
additional lease liabilities incurred during the period due to the commissioning of the hospital
expansion and new Comprehensive Cancer Centre at Mediclinic Airport Road Hospital in Abu
Dhabi. The Group continues to have headroom to all covenants, either waived or effective.

Further details on 1H22 performance and the outlook will be provided with the half-year results.

Financial performance
Note: All 1H22 figures represent the latest financial estimates and are approximates. None of
the figures have been reviewed and reported on by Mediclinic’s external auditors.


                                          1H22     1H21      1H20       1H22 vs 1H21 1H22 vs 1H20

                                                                              % movement

  Group
  Reported revenue (GBP'm)               1 580    1 411      1 515            12.0%          4.3%
  EBITDA margin (%)                      15.5%    12.1%      16.6%
  Hirslanden
  Revenue (CHF'm)                          910      853        871             6.7%          4.5%
  EBITDA margin (%)                      14.5%    13.7%      16.2%
  Inpatient admissions (movement)            -        -          -             3.2%          2.2%
  GBP/CHF average FX rate                 1.27     1.19       1.25
  Mediclinic Southern Africa
  Revenue (ZAR'm)                        9 380    6 972      8 578            34.5%          9.3%
  EBITDA margin (%)                      18.5%     8.2%      20.8%
  Paid patient days (movement)               -        -          -            29.2%        (3.1)%
  GBP/ZAR average FX rate                19.95    22.04      18.28
  Mediclinic Middle East
  Revenue (AED'm)                        2 000    1 760      1 616            13.6%         23.8%
  EBITDA margin (%)                      14.0%    12.7%      12.6%
  Inpatient admissions and day
  cases (movement)                           -        -          -            21.2%         17.2% 
  Outpatient cases (movement)                -        -          -            24.3%          6.4%
  GBP/AED average FX rate                 5.10     4.65       4.62
                                                                                               
1 The Group uses adjusted income statement reporting as non-IFRS measures in evaluating
  performance and as a method to provide shareholders with clear and consistent reporting. The
  Group's non-IFRS measures are intended to remove from reported earnings volatility
  associated with defined one-off incomes and charges.

2 Measures conversion of adjusted EBITDA into cash generated from operations.

Cautionary Statement
This announcement contains certain forward-looking statements relating to the business of the
Company and its subsidiaries, including with respect to the progress, timing and completion of
the Group’s development; the Group’s ability to treat, attract and retain patients and clients; its
ability to engage consultants and healthcare practitioners and to operate its business and
increase referrals; the integration of prior acquisitions; the Group’s estimates for future
performance and its estimates regarding anticipated operating results; future revenue; capital
requirements; shareholder structure; and financing. In addition, even if the Group’s actual
results or development are consistent with the forward-looking statements contained in this
announcement, those results or developments may not be indicative of the Group’s results or
developments in the future. In some cases, forward-looking statements can be identified by
words such as "could", "should", "may", "expects", "aims", "targets", "anticipates", "believes",
"intends", "estimates", or similar. These forward-looking statements are based largely on the
Group’s current expectations as of the date of this announcement and are subject to a number
of known and unknown risks and uncertainties and other factors that may cause actual results,
performance or achievements to be materially different from any future results, performance or
achievement expressed or implied by these forward-looking statements. In particular, the
Group’s expectations could be affected by, among other things, uncertainties involved in the
integration of acquisitions or new developments; changes in legislation or the regulatory regime
governing healthcare in Switzerland, South Africa, Namibia and the United Arab Emirates
("UAE"); poor performance by healthcare practitioners who practise at its facilities; unexpected
regulatory actions or suspensions; competition in general; the impact of global economic
changes; the impact of pandemics, including COVID-19; and the Group’s ability to obtain or
maintain accreditation or approval for its facilities or service lines. In light of these risks and
uncertainties, there can be no assurance that the forward-looking statements made in this
announcement will in fact be realised and no representation or warranty is given as to the
completeness or accuracy of the forward-looking statements contained in this announcement.

The Group is providing the information in this announcement as of this date, and disclaims any
intention to, and makes no undertaking to, publicly update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.

About Mediclinic International plc
Mediclinic is a diversified international private healthcare services group, established in South
Africa in 1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and
the UAE.

The Group’s core purpose is to enhance the quality of life.

Its vision is to be the partner of choice that people trust for all their healthcare needs.

Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the
continuum of care in such a way that the Group will be regarded as the most respected and
trusted provider of healthcare services by patients, medical practitioners, funders and
regulators of healthcare in each of its markets.

At 30 September 2021, Mediclinic comprised 74 hospitals, five subacute hospitals, two mental
health facilities, 19 day case clinics and 20 outpatient clinics. Hirslanden operated 17 hospitals
and four day case clinics in Switzerland with around 1 900 inpatient beds; Mediclinic Southern
Africa operations included 50 hospitals (three of which in Namibia), five subacute hospitals, two                                                                                                 
mental health facilities and 13 day case clinics (four of which operated by Intercare) across
South Africa, and around 8 600 inpatient beds; and Mediclinic Middle East operated seven
hospitals, two day case clinics and 20 outpatient clinics with around 1 000 inpatient beds in the
UAE. In addition, under management contracts Mediclinic Middle East operates one hospital in
Abu Dhabi and will open a 200-bed hospital in the Kingdom of Saudi Arabia in mid-2022.

The Company’s primary listing is on the London Stock Exchange ("LSE") in the United
Kingdom, with secondary listings on the JSE in South Africa and the Namibian Stock Exchange
in Namibia.

Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private
healthcare group based in the United Kingdom and listed on the LSE.

For further information, please contact:

Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181

Media queries
FTI Consulting
Ben Atwell/Ciara Martin – UK
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Corporate broker: Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd




                                                                                           

Date: 15-10-2021 08:00:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.

More from Mediclinic International plc


Join Listcorp to create a personalised news feed, follow your favourite companies, save useful news, and more.

By joining Listcorp you agree to our Terms & Conditions and Privacy Policy

Information on this Website is provided for general information purposes only and is not a substitute for professional advice. ASX Information (including company announcements and prices) is delayed by at least 20 minutes. JSE Information (including company announcements and prices) is delayed by at least 15 minutes. Reliance on the information you access on or from this Website is solely at your own risk. We make no representation or warranty in relation to the future performance of the companies that appear on this Website. Investment in securities involves risk and you should obtain independent professional legal, financial, investment or company advice before acting on any of the information you access on this Website. Using, browsing or otherwise accessing this Website is subject to our Terms and Conditions and our Privacy Policy.

© 2021 Listcorp. ABN 60 166 140 307

Never miss news from Mediclinic International plc (JSE:MEI) when you join Listcorp.